



QUARTERLY COMPLIANCE REPORT ON CORPORATE GOVERNANCE

Name of the Listed Entity : ASTRAZENECA PHARMA INDIA LIMITED
 Quarter ending : June 30, 2021

ANNEXURE 1

I. Composition of Board Directors													
Title (Mr./Ms.)	Name of the Director	PAN	DIN	Category (Chairperson/Executive/Non-Executive/Independent/Nominee)	Initial date of appointment	Date of Re-appointment	Date of cessation	Tenure*	Date of Birth	No. of Directorship in listed entities including this listed entity (Refer Regulation 17A(1) of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity [in reference to provision to regulation 17A(1)]	No. of Memberships in Audit/Stakeholder Committee(s) including this listed entity(Refer Regulation 26(1) of Listing Regulations)	No. of Post of Chairperson in Audit/Stakeholder Committee held in listed entities including this listed entity(Refer Regulation 26(1) of Listing Regulations)
Mr.	NARAYAN KEELVEEDHI SESHADRI	AAVPS2486D	00053563	Non-Executive/Independent	06-Jun-12	30-Sep-19	-	5 years	13-Apr-57	4	4	7	3
Ms.	REVATHY ASHOK	ACLPR3951Q	00057539	Non-Executive/Independent	02-Dec-16	-	-	5 years	16-Jan-59	4	4	8	2
Ms.	KIMSUKA NARASIMHAN	AAKPK7372B	02102783	Non-Executive/Independent	02-Feb-17	-	-	5 years	03-May-64	2	2	1	0
Mr.	GAGANDEEP SINGH BEDI	AAKPB3168Q	07844333	Executive	01-Jul-17	01-Jul-20	-	3 years	26-Dec-71	1	-	1	0
Ms.	WEIYING SARAH WANG	PAN not available	08369289	Non-Executive	13-Mar-19	-	-	-	17-Dec-75	1	-	2	1
Mr.	ANKUSH NANDRA	PAN not available	08737981	Non-Executive	18-May-20	-	-	-	06-Dec-71	1	-	0	0
Mr.	RAJESH MARWAHA	AAAPM1413D	01458768	Executive	02-Dec-16	02-Dec-19	-	3 years	26-Mar-63	1	-	1	0

Whether Regular chairperson appointed : Yes
 Whether Chairperson is related to managing director or CEO : No

III. Meeting of Board of Directors					
Date(s) of Meeting (if any) in the previous quarter	Date(s) of Meeting (if any) in the relevant quarter	Whether requirement of Quorum met	Number of Directors present	Number of independent directors present	Maximum gap between any two consecutive meetings (in number of days)
8-Feb-2021	25-May-2021	Yes	7	3	74
11-Mar-2021		Yes	7	3	-

III. Meetings of Committees					
Date(s) of Meeting of the Committee in the relevant quarter	Whether requirement of Quorum met	Number of Directors present	Number of independent directors present	Date(s) of Meeting (if any) in the previous quarter	Maximum gap between any two consecutive meetings (in number of days)
Audit Committee					
20-Apr-2021	Yes	3	2	8-Feb-2021	34
25-Apr-2021	Yes	3	2		
29-Jun-2021	Yes	3	2		
Nomination & Remuneration Committee					
-	-	-	-	11-Mar-2021	-
-	-	-	-	8-Feb-2021	-
Risk Management Committee					
-	-	-	-	8-Feb-2021	-

V. Related Party Transactions	
Subject	Compliance status (Yes / No / NA) refer note below
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT	Yes
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit committee	Yes

Details of material transactions with Related Party for the quarter ended June 30, 2021

Name of the Related Party: **AstraZeneca UK Limited**

Type of Transaction	Amount (INR)
Imports	353,324,841
Payable of Expenses	13,183,893
Reimbursement of Expenses	3,227,410
Total	369,736,144

Affirmations

1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015
2. The Composition of the following committees is in terms of SEBI (listing Obligations and Disclosure requirements) Regulations, 2015
 - a) Audit Committee
 - b) Nomination & Remuneration Committee
 - c) Stakeholders Relationship Committee
 - d) Risk Management Committee
3. The Committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements Regulations, 2015
4. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015
5. This report and /or the report submitted in the previous quarter has been placed before Board of Directors.

Any comments/observations/advice of Board of Directors may be mentioned here: NIL

For **AstraZeneca Pharma India Limited**

Sd/-

Pratap Rudra

Company Secretary & Legal Counsel